Tomas J. Heyman is a director of Akero Therapeutics Inc.
Person profile
Roles
Address
South San Francisco, California
Employees
SEC CIK
Latest filings (excl ownership)
No filings
Latest ownership filings
144
Legend Biotech Corp
12 Dec 23
4
Akero Therapeutics, Inc.
27 Jun 23
4
Akero Therapeutics, Inc.
21 Jun 23
144
Akero Therapeutics, Inc.
16 Jun 23
4
Xilio Therapeutics, Inc.
13 Jun 23
4
OptiNose, Inc.
9 Jun 23
4
EXELIXIS, INC.
2 Jun 23
3
EXELIXIS, INC.
2 Jun 23
4
Invivyd, Inc.
25 May 23
3
Xilio Therapeutics, Inc.
16 Sep 22
Recent insider trades
Date | Company | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Jun 23 | AKRO Akero Therapeutics | Stock Option Common Stock | Grant | Acquire A | No | No | 50.83 | 15,000 | 762.45 k | 15,000 |
16 Jun 23 | AKRO Akero Therapeutics | Common Stock | Sell | Dispose S | No | No | 54.6742 | 26,000 | 1.42 mm | 0 |
16 Jun 23 | AKRO Akero Therapeutics | Common Stock | Option exercise | Acquire M | No | No | 25.04 | 26,000 | 651.04 k | 26,000 |
16 Jun 23 | AKRO Akero Therapeutics | Stock Option Common Stock | Option exercise | Dispose M | No | No | 25.04 | 26,000 | 651.04 k | 0 |
12 Jun 23 | XLO Xilio Therapeutics | Stock Option Common Stock | Grant | Acquire A | No | No | 2.8 | 13,200 | 36.96 k | 13,200 |
8 Jun 23 | OPTN OptiNose | Stock Option Common Stock | Grant | Acquire A | No | No | 1.18 | 53,500 | 63.13 k | 53,500 |